Considering of function compensation of CDK7 and 9 in cancer cell proliferation, continuous effort to improve in vivo exposure of 2-((4-sulfamoylphenyl)amino)-pyrrolo[2,3-d]pyrimidine derivatives and screening effective anti-proliferative partners is worthy to provide promising regimens for PDAC treatment. The gene discussed is CDK7; the disease is cancer.